Day: February 24, 2022

  Q4-2021   Key ResultsRevenue (millions) $128.7   • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS $0.05  Non-GAAP EPS $0.47       PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fourth quarter ended December 31, 2021, the Company reported revenue of $128.7 million, an increase of 8.4% compared to $118.7 million reported for...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on March 4, 2022, to discuss the company’s financial results for the fourth quarter and year ended December 31, 2021. A news release containing the results will be issued before the open of the U.S. equity markets and will be available on http://ir.silvercrestgroup.com/. Chairman, Chief Executive Officer and President Richard R. Hough III and Chief Financial Officer Scott A. Gerard will review the quarterly results during the call. Immediately after the prepared remarks, there will be a question and answer session for analysts and institutional investors. Analysts, institutional investors and the general public may listen to the call by dialing 1-844-836-8743 or...

Fourth quarter revenue Up 24% to $20.3 million, gross profit margin of 61% Introduction of key performance indicators (KPIs) representing “land and expand” strategy with key customer accounts Cash flow positive from operations of $0.7 million in 2021ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2021.Key Performance Indicators (KPIs)*    FY21  FY20   Average revenue per top 20 pharmaceutical manufacturers    $2.5M  $1.9M   Percent top 20 pharmaceutical manufacturers that are clients  95 % 85 %  Top 20 pharmaceutical percent of total net revenues 77 % 76 %  Net revenue retention  127%    160 %  Revenue...

Gevo to Host Conference Call Today at 4:30 p.m. EDT/2:30 p.m. MDT ENGLEWOOD, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) today announced financial results for the fourth quarter of 2021 and summarized recent corporate highlights. Recent Corporate HighlightsOn December 7, 2021, Kolmar Americas Inc and Gevo entered into a financeable fuel supply agreement for 45 million gallons per year of renewable, energy-dense liquid hydrocarbons. On November 16, 2021, Gevo signed a memorandum of understanding (MoU) with Sweetwater Energy, Inc., regarding the use of sustainably sourced agricultural residues and woody biomass as a feedstock for producing cellulosic alcohols and energy-dense renewable liquid hydrocarbons. On October 25, 2021, ADM, a global leader in nutrition and agricultural origination and processing, and...

Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as followsFILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNFα in ulcerative colitis (UC) in H1 2022 LOMBARD monotherapy trial in UC and CASTRO combination trial with anti-TNFα in rheumatoid arthritis (RA) in H2 2022Phase 1 ongoing for second product candidate, oral AMT-126, with program update in H1 2022 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. “We are looking forward to a catalyst-rich year in 2022 for AMT,” said Tahir Mahmood, Ph.D.,...

FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4’21, plus $5.4 Million Recognized from Ji Xing Pharmaceuticals (Ji Xing) License Agreement in Q4’21 Over 5,500 TYRVAYA Prescriptions Filled; Prescriptions Written by Approximately 1,900 Unique Eye Care Professionals in November and December 2021 $50 Million Drawn on Second Tranche from OrbiMed Royalty & Credit Opportunities III, LP (OrbiMed), Cash Received on November 4, 2021 Continue to Enroll OLYMPIA Phase 2 Clinical Trial, Study Results Expected in 2H 2022 Conference Call and Webcast Scheduled for 4:30 pm ET TodayPRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”,...

Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today named Valerie Palmieri as Executive Chair of the Board, and Nicole Sandford as President and CEO of the Company. Jim LaFrance, Aspira’s current Board Chair, will step into the role of Lead Independent Director and Audit Committee Chair. All changes will be effective as of March 1, 2022. “I am thrilled to announce Valerie as our new Executive Chair of the Board. During her eight years as CEO, she has taken the company to a new level with her passion and commitment to establishing a premier women’s health company. As we continue to evolve and grow under her watch,...

Recent Highlights:Signed a definitive agreement with ACME Metal Enterprise Co., Ltd. (ACME) to deploy and license AquaRefining equipment and technologies at its facility in Keelung, Taiwan.Commenced AquaRefining equipment shipments to first Asia Pacific Licensee, ACME MetalReached agreement to lease-to-sell AquaRefinery plant in Tahoe-Reno Industrial Center for $14.5-15.5M to emerging Li-Ion recycler LiNiCo. Received non-refundable deposit of $1.25M plus monthly lease payments and expect to receive full payment between October, 2022 and March, 2023 with a $1M incentive for LiNiCo to exercise option prior to October 1, 2022Made an initial investment in LiNiCo in February, 2021Developed and filed provisional patent for work on AquaRefining for lithium-ion battery recycling which has yielded promising results, meeting vital benchmarks...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights:Achieved total revenue of $79.2 million for the three months ended December 31, 2021, increasing 35% over prior year fourth quarter Delivered full year revenue of $296.4 million, an increase of 54% compared with full year 2020 revenue Provided approximately 41,900 AlloSure and AlloMap patient results in the fourth quarter, growing 67% from prior year quarter. Full year 2021 AlloSure and AlloMap testing volumes grew year over year by 94%...

Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumab Presented encouraging preclinical combinatorial anti-tumor activity with MGD024 at ASH in December Conference call scheduled for today at 4:30 p.m. ET.ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2021. “We are excited about our 2022 plans for our B7-H3-directed programs for the potential treatment of multiple...